Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

Completed · Phase 3

Conditions studied: Nephrotic Syndrome

In brief

In childhood nephrotic syndrome, the kidneys leak protein, causing body swelling and a variety of possible complications such as infection, blood clots, and kidney failure. The first-line treatment for nephrotic syndrome is corticosteroids. Many children respond to prednisone treatment, but the disease comes back (relapses) when the prednisone is stopped or the dose is reduced. Children with frequently relapsing or steroid dependent nephrotic syndrome are at risk for toxicity from frequent exposure to corticosteroids. Currently, the standard treatment for frequently relapsing and steroid dependent nephrotic syndrome involves a variety of medications that suppress the immune system, which can produce serious side effects. We propose a study to examine the effects of a different medication, ACTH, on nephrotic syndrome. ACTH is a hormone naturally found in the body. Recently, in adult studies, ACTH has been shown to be effective for the treatment of nephrotic syndrome. It has also been shown to have mild and reversible side effects. ACTH is potentially an attractive therapeutic alternative for the treatment of frequently relapsing and steroid dependent nephrotic syndrome in children. Our study will randomly assign patients with frequently relapsing or steroid dependent nephrotic syndrome to either ACTH treatment or no treatment. This will allow us to study the effects of ACTH on this disease and its side effects, by comparing how patients do on ACTH treatment versus no treatment. We hypothesize that ACTH gel is superior to no treatment in maintaining remission in children with frequently relapsing or steroid dependent nephrotic syndrome.

Key facts

Study ID

NCT02132195

Run by

Emory University

People needed

31

Starts

2014-05-01

Expected to finish

2018-03-01

Last updated by the study team

2019-05-29

Who can join

Age: 2 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >1 year at onset of nephrotic syndrome
• Age 2-20 years at time of randomization
• Estimated glomerular filtration rate (GFR) > 50 ml/min/1.73 m2 at most recent measure prior to randomization (Schwartz formula)
• Steroid responsive nephrotic syndrome throughout clinical course (never required a second agent to attain remission of a relapse of nephrotic syndrome)
• History of frequently relapsing or steroid dependent nephrotic syndrome (defined as 2 or more relapses within 6 months after initial therapy or 4 or more relapses in any 12 month period OR relapse during taper or within 2 weeks of discontinuing prednisone).
• Patient is currently in relapse of nephrotic syndrome or had a relapse within the last 4 months (defined as an increase in the first morning urine protein to creatinine ratio ≥2 or Albustix reading of ≥2 for 3 or 5 consecutive days).

You may not qualify if…

• Prior treatment with ACTH.
• Cyclophosphamide or rituximab within the last 4 months.
• Lactation, pregnancy, or refusal of birth control in females with child-bearing potential
• Planned treatment with live or live-attenuated vaccines once enrolled in the study.
• Participation in another therapeutic trial concurrently or 30 days prior to randomization
• Active/serious infection (including, but not limited to Hepatitis B or C, HIV)
• Malignancy concurrently or within the last 2 years.
• Blood pressure >95% for age/height while receiving maximal doses of 3 or more medications.
• Prior diagnosis of diabetes mellitus (Type I or II) or fasting glucose >200mg/dL
• Organ transplantation
• Contraindications to Acthar: scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical hyperfunction
• Secondary cause of nephrotic syndrome (e.g., SLE)
• Biopsy demonstrating a diagnosis other than minimal change, focal segmental glomerulosclerosis (FSGS) or a variant (mesangial proliferation, Immunoglobulin M nephropathy)
• Inability to consent/assent -

Where it is running

• Pediatric Nephrology of Alabama, PC. — Birmingham, Alabama, United States
• University of California, Los Angeles — Los Angeles, California, United States
• Nemours/AI duPont Hospital for Children — Wilmington, Delaware, United States
• Nemours Children's Hospital — Orlando, Florida, United States
• Emory University — Atlanta, Georgia, United States
• Riley Hospital for Children — Indianapolis, Indiana, United States
• Boston Children's Hopsital — Boston, Massachusetts, United States
• Helen DeVos Children's Hospital at Spectrum Health — Grand Rapids, Michigan, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Children's Mercy — Kansas City, Missouri, United States
• Children's Hospital at Montefiore — The Bronx, New York, United States
• Duke Children's Health Center — Durham, North Carolina, United States
• East Carolina University — Greenville, North Carolina, United States
• Driscoll Children's Hospital — Corpus Christi, Texas, United States
• Texas Children's Hospital — Houston, Texas, United States
• Children's Hospital of Richmond at VCU — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.